CoChat
Sign Up
Cited by 311Treatment of Major DepressionMental Health Treatment and AccessAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 134 of the 137 references it cites were found in a registry or an index.

Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents

Papakostas, George I., Thase, Michael E., Fava, Maurizio, Nelson, J. Craig, Shelton, Richard C.·2007·Biological Psychiatry
DOI 10.1016/j.biopsych.2007.03.027
Open this paper in CoChat — free account

Abstract

Background Recent studies suggest that the treatment of major depressive disorder (MDD) with newer antidepressant drugs that simultaneously enhance norepinephrine and serotonin neurotransmission might result in higher response and remission rates than the selective serotonin reuptake inhibitors (SSRIs). The goal of our work was to compare response rates among patients with MDD treated with either of these two broad categories of antidepressant drugs. Methods Medline/Pubmed, EMBase, clinical trial registries, program syllabi from major psychiatric meetings held since 1995, and documents from relevant pharmaceutical companies were searched for double-blind, randomized trials comparing a newer serotonergic-noradrenergic antidepressant drug (venlafaxine, duloxetine, milnacipran, mirtazapine, mianserin, or moclobemide) with an SSRI for MDD. Results Ninety-three trials (n = 17,036) were combined using a random-effects model. Treatment with serotonergic + noradrenergic antidepressant drugs was more likely to result in clinical response than the SSRIs (risk ratio [RR] = 1.059; response rates 63.6% versus 59.3%; p = .003). There was no evidence for heterogeneity among studies combined (p = 1.0). Excluding each individual agent did not significantly alter the pooled RR. With the exception of duloxetine (.985), RRs for response for each individual serotonergic + noradrenergic antidepressant drug were within the 95% confidence interval of the pooled RR (1.019-1.101). Conclusions Serotonergic-noradrenergic antidepressant drugs seem to have a modest efficacy advantage compared with SSRIs in MDD. With the Number Needed to Treat (NNT) statistic as one indicator of clinical significance, nearly 24 patients would need to be treated with dual-action antidepressant drugs instead of SSRIs in order to obtain one additional responder. This difference falls well below the mark of NNT = 10 suggested by the United Kingdom's National Institute of Clinical Excellence but nonetheless might be of public health relevance given the large number of depressed patients treated with SSRI /serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant drugs. Further research is needed to examine whether larger differences between classes of antidepressant drugs might exist in specific MDD sub-populations or for specific MDD symptoms.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2007.03.027

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 137 references

3 of the 137 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

  1. Tylee, 1997, A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice, Primary Care Psychiatry, 3, 51
  2. McPartlin, 1998, A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice, Primary Care Psychiatry, 4, 127
  3. Benattia, 2004, Using treatment algorithms to achieve remission of depression with venlafaxine XR or SSRIs, Int J Neuropsychopharmacol, 7, s167
  4. Gersing, 2006, Effectiveness or escitalopram vs venlafaxine in major depression in a real world clinical setting, Int J Neuropsychopharmacol, 9, s214
  5. Keller, 2004, Comparing the efficacy of venlafaxine ER and fluoxetine for acute continuation and maintenance therapy in recurrent unipolar major depression, Neuropsychopharmacology, 29, s148
  6. Nierenberg, 2005, Onset of antidepressant action and acute efficacy and safety of duloxetine versus escitalopram and placebo in the treatment of major depressive disorder, Neuropsychopharmacology, 30, s142
  7. Papakostas, 2006, Does the probability of receiving placebo influence the likelihood of responding to placebo or clinical trial outcome?, Neuropsychopharmacology, 31, s158

Cited by

Sorted by citations

Items 101–200 of 311

Related

See all

Metadata

Authors
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C.
Affiliations
  • Harvard University (US)
  • University of Pittsburgh Medical Center (US)
  • University of California, San Francisco (US)
  • Vanderbilt University (US)
Corresponding author
Papakostas, George I.
ORCID
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2007-12
Volume
62
Issue
11
Pages
1217-1227
ISSN
0006-3223 (ISSN-L)
DOI
10.1016/j.biopsych.2007.03.027
OpenAlex
W1996039326
Cited by
308
References
137
Citations by year
2026: 3 · 2025: 5 · 2024: 11 · 2023: 6 · 2022: 11 · 2021: 5 · 2020: 4 · 2019: 13 · 2018: 6 · 2017: 17 · 2016: 13 · 2015: 23 · 2014: 14 · 2013: 31 · 2012: 24
FWCI
3.32
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (K23MH069629)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
major depressive disorder, selective serotonin reuptake inhibitors, venlafaxine, duloxetine, milnacipran, mirtazapine, mianserin, moclobemide, antidepressant efficacy, treatment response, remission, number needed to treat, norepinephrine uptake
MeSH terms
Antidepressive Agents, Data Interpretation, Statistical, Depressive Disorder, Major, Major Depressive Disorder, Humans, Norepinephrine, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review